Global Veterinary Pharmaceuticals market size is expected to reach $50.59 billion by 2029 at 7.5%, segmented as by type, veterinary vaccines, veterinary antibiotics, veterinary parasiticides, other veterinary pharmaceuticals

The Veterinary Medicine Market report segments the industry into By Product Type (Drugs, Vaccines, Medicated Feed Additives), By Animal Type (Companion Animals, Livestock Animals), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). Five years of historical data and market forecasts are included.

The report covers Veterinary Compounds Trends and the Market is Segmented by Product Type (Anti-infectives, Anti-inflammatory, Parasiticides, Vaccines, and Others), Route of Administration (Oral, Parenteral, and Topical), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market provides the value (in USD million) for the above-mentioned segments.

The global market size for animal medicine amounted to around ** billion U.S. dollars in 2022. It was forecasted that the market would expand to some ** billion dollars by 2032, equivalent to a compound annual growth rate (CADR) of *** percent. The animal medicine industry is comprised of segments such as veterinary vaccines, veterinary antibiotics, and veterinary parasiticides.

Key Takeaways

• Market Size: The Veterinary Medicine Market is projected to reach USD 97.0 billion by 2033, up from USD 47.5 billion in 2023, growing at a CAGR of 7.4% from 2024 to 2033.
• Market Growth: The market is experiencing steady growth, driven by increasing demand for veterinary care and rising awareness about animal health.
• Product Analysis: In 2023, drugs dominated the market, holding a 58.2% share, highlighting their essential role in animal health management.
• Animal Analysis: Livestock animals accounted for 56.8% of the veterinary medicine market share in 2023, reflecting their significant role in veterinary treatments.
• Route of Administration: Parenteral administration led the market with a 58% share in 2023, showing the preference for injectable treatments in veterinary care.
• End-Use Analysis: Hospitals and clinics remained the dominant end-users of veterinary medicine, capturing a 46.8% market share in 2023.
• Regional Analysis: North America held a 38.2% share of the veterinary medicine market in 2023, remaining the leading region for veterinary care.

The global sales of Over-The-Counter (OTC) Veterinary Drugs is estimated to be worth USD 10.3 billion in 2025 and anticipated to reach a value of USD 22.4 billion by 2035. Sales are projected to rise at a CAGR of 8.1% over the forecast period between 2025 and 2035.

Attributes	Key Insights
Industry Size (2025E)	USD 10.3 billion
Industry Value (2035F)	USD 22.4 billion
CAGR (2025 to 2035)	8.1%

Semi Annual Market Update

Particular	Value CAGR
H1	8.3% (2024 to 2034)
H2	8.6% (2024 to 2034)
H1	8.1% (2025 to 2035)
H2	8.8% (2025 to 2035)

Country-wise Insights

Countries	CAGR Value (2025 to 2035)
United States	3.2%
United Kingdom	3.4%
Germany	3.6%
Japan	4.2%
China	6.5%
India	7.8%

Category-wise Insights

By Drug Class	Value Share (2025)
Antiparasitics	10.9%

By Product form	Value Share (2025)
Oral	77.3%

Global Veterinary Pharmaceuticals Market is anticipated to experience remarkable expansion, with a projected Compound Annual Growth Rate (CAGR) of 8.07% from 2025 to 2033. According to the market analysis, the market size is forecasted to reach USD 77.62 Billion by the end of 2033, up from USD 38.6 Billion in 2024.

The Global Veterinary Pharmaceuticals market size to cross USD 77.62 Billion by 20

Veterinary Medicine Market valuation is estimated to reach USD 38.07 Bn in 2025 and is anticipated to grow to USD 56.12 Bn by 2032 with steady CAGR of 5.7%.

Saudi Arabia Veterinary Medicine Market was valued at USD 180.12 Million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 4.65% through 2030.

Pages	85
Market Size	2024: USD 180.12 Million
Forecast Market Size	2030: USD 237.15 Million
CAGR	2025-2030: 4.65%
Fastest Growing Segment	Companion
Largest Market	Northern & Central
Key Players	1. MAS Group 2. Saudi Pharmaceutical Industries 3. The Arab Pesticides and Veterinary Drugs Mfg. Co (Mobedco) 4. Merck Animal Health (MSD) 5. Boehringer Ingelheim GmbH Saudi Arabia 6. Elanco Animal Health Saudi Arabia 7. Virbac Saudi Arabia 8. Montajat Pharmaceuticals 9. Pharma Care Limited 10. Al-Takamul Agriculture Company

Veterinary Pharmaceuticals Market Outlook

The global veterinary pharmaceuticals market size is anticipated to grow significantly from USD 31.8 billion in 2023 to USD 50.2 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.2%. The market is buoyed by factors such as the increasing pet ownership, rising awareness about animal health, and substantial investments in veterinary healthcare by both public and private sectors. The demand for veterinary pharmaceuticals is further accelerated by the surge in zoonotic diseases and the need for sustainable livestock farming practices that ensure the well-being of animals involved in food production. Technological advancements in veterinary medicine are also playing a crucial role in enhancing the efficacy of pharmaceuticals, thereby contributing to market growth.

One of the primary growth drivers in the veterinary pharmaceuticals market is the increasing human-animal bond leading to a rise in pet ownership globally. This trend is particularly noticeable in urban areas, where pets are seen as companions and family members, leading to higher expenditure on their health and well-being. Moreover, the rising incidence of zoonotic diseases, which can be transmitted from animals to humans, has heightened the awareness and need for effective veterinary pharmaceuticals. Governments and health organizations worldwide are investing in preventive measures and treatments for such diseases, propelling the demand for veterinary drugs. Additionally, the development of innovative pharmaceuticals that offer better treatment outcomes with fewer side effects is gaining traction, encouraging pet owners to invest in these products.

Another significant factor contributing to the growth of the veterinary pharmaceuticals market is the expanding livestock industry. With the global population expected to reach new heights, the demand for animal-based food products is on the rise, necessitating efficient animal husbandry practices. This has led to an increased focus on enhancing the productivity and health of livestock animals through the use of veterinary pharmaceuticals. The emergence of new pathogens and the growing resistance to existing drugs are pushing the need for novel and effective treatments, which is further driving innovation in this sector. Companies are increasingly investing in research and development to cater to the evolving needs of the livestock industry, thereby fostering market expansion.

Furthermore, the regulatory environment for veterinary pharmaceuticals is evolving, with several countries streamlining their approval processes to expedite the availability of essential animal health products. The introduction of stringent regulations aimed at ensuring the safety and efficacy of veterinary drugs is expected to build consumer trust and drive market growth. Additionally, initiatives to curb the use of antibiotics and promote responsible medication among veterinarians are encouraging the development of alternative therapies, including vaccines and biologics, which are gaining popularity. This shift towards safer and sustainable practices is likely to create new opportunities for players in the veterinary pharmaceuticals market.

Product Type Analysis

The veterinary pharmaceuticals market is segmented into various product types, including anti-infectives, anti-inflammatories, parasiticides, vaccines, and others. Anti-infectives remain a vital component of veterinary pharmaceuticals, crucial for managing and treating infections in both companion and livestock animals. The increasing prevalence of bacterial infections and the rise in antimicrobial resistance have underscored the need for innovative anti-infective agents. Pharmaceutical companies are focusing on developing advanced formulations that are not only effective but also minimize the development of resistance, ensuring long-term effectiveness. The launch of new and improved anti-infectives is anticipated to drive this segment significantly over the forecast period.

Anti-inflammatories are another essential category within veterinary pharmaceuticals, primarily used to manage pain and inflammation in animals. The rising awareness about animal welfare and the need to provide better quality of life for pets and livestock are driving the demand for these drugs. Advances in drug delivery systems and the introduction of non-steroidal anti-inflammatory drugs (NSAIDs) with improved safety profiles have contributed to the growth of this segment. As more pet owners seek pain management solutions for their aging pets, the demand for effective anti-inflammatory medications is expected to rise steadily, further su

Global Veterinary Medicine Market is poised to witness substantial growth, reaching a value of USD 46.3 Billion by the year 2033, up from USD 24.01 Billion attained in 2024. The market is anticipated to display a Compound Annual Growth Rate (CAGR) of 7.57% between 2025 and 2033.

The Global Veterinary Medicine market size to cross USD 46.3 Billion by 2033. [https://edison.valuemarketresearch.com//

Uncover Market Research Intellect's latest Veterinary Pharmaceuticals Market Report, valued at USD 60 billion in 2024, expected to rise to USD 85 billion by 2033 at a CAGR of 5.0% from 2026 to 2033.

Global Animal Medicine market size is expected to reach $69.05 billion by 2029 at 6.1%, segmented as by medicine, veterinary pharmaceuticals, feed additives

The global veterinary pharmaceuticals market is experiencing robust growth, driven by increasing pet ownership, rising pet healthcare expenditure, and the growing prevalence of zoonotic diseases. The market size in 2025 is estimated at $50 billion, reflecting a significant expansion from previous years. This growth is projected to continue at a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033, pushing the market value to an estimated $85 billion by 2033. Key factors contributing to this expansion include advancements in veterinary medicine leading to the development of innovative therapies, a rising demand for companion animal healthcare services, and increased government initiatives to support animal health. Furthermore, the increasing awareness among pet owners about preventive healthcare measures and the availability of pet insurance are driving market growth. Major players like Zoetis, Merial, Boehringer Ingelheim, and Elanco Animal Health dominate the market, constantly innovating and expanding their product portfolios. The market is segmented by animal type (companion animals, livestock, poultry, etc.), drug type (antibiotics, antiparasitics, vaccines, etc.), and therapeutic area. While the market faces certain restraints, such as stringent regulatory approvals and the potential for price fluctuations in raw materials, the overall outlook remains positive, fueled by the aforementioned growth drivers and the increasing focus on animal welfare globally. The Asia-Pacific region is expected to witness significant growth due to rising pet ownership and improving veterinary infrastructure.

According to Cognitive Market Research, the global Veterinary Drugs market size will be USD 51421.8 million in 2025. It will expand at a compound annual growth rate (CAGR) of 8.80% from 2025 to 2033.

North America held the major market share for more than 40% of the global revenue with a market size of USD 19026.07 million in 2025 and will grow at a compound annual growth rate (CAGR) of 6.6% from 2025 to 2033.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 14912.32 million.
APAC held a market share of around 23% of the global revenue with a market size of USD 12341.23 million in 2025 and will grow at a compound annual growth rate (CAGR) of 10.8% from 2025 to 2033.
South America has a market share of more than 5% of the global revenue with a market size of USD 1954.03 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.8% from 2025 to 2033.
The Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 2056.87 million in 2025 and will grow at a compound annual growth rate (CAGR) of 8.1% from 2025 to 2033.
Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 1131.28 million in 2025. It will grow at a compound annual growth rate (CAGR) of 8.5% from 2025 to 2033.
Anti-infective category is the fastest growing segment of the Veterinary Drugs industry

Market Dynamics of Veterinary Drugs Market

Key Drivers for Veterinary Drugs Market

Rising Pet Ownership and Humanization of Animals to Boost Market Growth

The most significant driving force behind the growth of the veterinary drugs market is the global rise in pet ownership, accompanied by the increasing trend of animal humanization. More people are treating pets as family members and prioritizing their health and well-being. This shift has driven demand for better healthcare, preventive medicine, and therapeutic treatments for animals, especially in urban and high-income households. Furthermore, as companion animals live longer due to improved care, there's a growing need for chronic disease management, including treatments for arthritis, diabetes, and cancer. Additionally, pet insurance is becoming more common, making advanced veterinary care more accessible and affordable. This has encouraged pet owners to opt for high-quality veterinary drugs, supporting market expansion.

Expansion of Livestock Farming and Zoonotic Disease Control To Boost Market Growth

The expansion of commercial livestock farming and the global emphasis on food security have significantly driven the veterinary drugs market. As demand for animal protein, such as meat, milk, and eggs, rises, farmers are investing more in the health of their herds and flocks to boost productivity and reduce losses. Veterinary drugs, including antibiotics, vaccines, and antiparasitics, are critical in ensuring animal health and preventing disease outbreaks. Moreover, the growing threat of zoonotic diseases—those that can transfer from animals to humans—has led governments and health organizations to invest in preventive veterinary healthcare. Events such as avian flu, swine fever, and bovine spongiform encephalopathy have highlighted the need for robust veterinary drug protocols.

Restraint Factor for the Veterinary Drugs Market

Stringent Regulatory Approvals and Compliance Requirements Will Limit Market Growth

The veterinary drugs market is significantly restrained by the complex and lengthy regulatory approval processes enforced by government bodies such as the US FDA's Center for Veterinary Medicine (CVM) and the European Medicines Agency (EMA). These regulations ensure drug safety and efficacy but also involve substantial costs, documentation, and long timelines for market entry. Pharmaceutical companies must undergo rigorous pre-clinical and clinical testing, along with Good Manufacturing Practice (GMP) compliance, before securing approval. This not only delays time-to-market but can also deter smaller players due to high upfront investment. Additionally, post-market surveillance and pharmacovigilance requirements add to operational costs. The regulatory variations between countries further complicate global market expansion strategies.

Impact of Trump Tariffs on the Veterinary Drugs Market

The imposition of 25% tariffs on pharmaceutical imports by the US is expected to d...

Veterinary pharmaceutical manufacturers have endured their fair share of challenging trading conditions. Demand from downstream beef, cattle and sheep farming has been volatile thanks to seasonal weather patterns that battered farmers with either prolonged drought conditions or flooding. Stringent regulatory controls, higher compliance costs and growing consolidation pressures have compounded this issue, prompting several major global pharmaceutical companies to divest their veterinary pharmaceutical operations. Yet it hasn't all been bad news for manufacturers, with a surge in pet ownership amid COVID-19 lockdowns fuelling demand for products for companion animals. Shifting trends towards pet humanisation, where companion animals are treated as part of the family, and consumers’ willingness to spend more on pet health and wellbeing have supported sales. The pandemic also drove a heightened focus on protecting both human and animal populations, spurring the development of innovative vaccines and greater use of preventative care products to reduce pathogen contamination risks. All-in-all, revenue is anticipated to have grown at an annualised 2.0% over the past five years and is expected to total $1.3 billion in 2024-25, when it will grow by an estimated 3.9%. Going forwards, industry revenue is forecast to rise at an annualised 2.9% over the five years through 2029-30 to total $1.5 billion. The rising prevalence of animal and zoonotic diseases will drive the development of new animal health vaccines and products, as will new technologies like biologics. Ongoing product innovations and advanced technology that help livestock farmers monitor animal health issues will become a potential growth area for manufacturers. In light of the recent boom in pet ownership during the pandemic, rising household discretionary incomes, higher veterinarian numbers and a desire for quality pet care are set to fuel higher spending on veterinary pharmaceuticals. However, ongoing regulatory compliance will limit profitability.

Global veterinary pharmaceuticals market size is expected at reach $64,188.6 million by 2033 at a growth rate of 7.9%

Europe Veterinary Pharmaceuticals Market has valued at USD 6.62 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.03% through 2028.

Pages	130
Market Size
Forecast Market Size
CAGR
Fastest Growing Segment
Largest Market
Key Players

Over-The-Counter (OTC) Veterinary Drugs Market Share Analysis Outlook from 2025 to 2035

Attribute	Details
Projected Value by 2025	USD 10259.19 million

Global Market Share by Key Players

Global Market Share, 2025	Industry Share %
Top 3 (Zoetis, Merck Animal Health, Boehringer Ingelheim)	52%
Top 5 (Zoetis, Merck Animal Health, Boehringer Ingelheim, Elanco and Ceva Santé Animale)	75%
Chinese Suppliers (Hengrui Medicine Co., Ltd., Tianjin Teda Pharmaceutical Co., Ltd., Beijing Tongrentang Co., Ltd.and others)	10.8%
Emerging & Regional Players	14.2%

Tier-Wise Company Classification, 2025

Tier	Market Share(%)
Tier 1 (Zoetis, Merck Animal Health, Boehringer Ingelheim)	40.0%
Tier 2 (Elanco, Ceva Santé Animale)	33.3%
Tier 3 (Regional players, startups)	27%

The global veterinary active pharmaceutical ingredients (API) market is experiencing robust growth, driven by increasing pet ownership, rising animal healthcare expenditure, and the growing prevalence of zoonotic diseases. The market's expansion is further fueled by advancements in veterinary medicine, leading to the development of novel and more effective APIs. While precise figures for market size and CAGR aren't provided, a reasonable estimate, considering the industry's typical growth rates and the involvement of major players like Huvepharma and Qilu Pharmaceutical, would place the 2025 market size at approximately $2.5 billion, with a projected CAGR of 7-8% over the forecast period (2025-2033). This growth is segmented across various API types catering to different animal species and health conditions, with anti-infectives, parasiticides, and cardiovascular drugs being prominent segments. The market's geographical distribution is expected to be concentrated in regions with high animal populations and established veterinary infrastructure, with North America and Europe currently holding significant shares. However, several restraining factors influence market growth. Stringent regulatory approvals for new APIs, fluctuating raw material prices, and the potential for generic competition can all pose challenges. Despite these challenges, the long-term outlook for the veterinary API market remains positive, largely due to ongoing innovation in drug development and the increasing demand for advanced animal healthcare solutions. Key industry players are investing heavily in R&D, focusing on developing novel APIs with improved efficacy, safety, and bioavailability. This ongoing innovation, coupled with the overall expansion of the veterinary pharmaceutical industry, will likely drive sustained market growth in the coming years. Strategic partnerships, mergers, and acquisitions within the industry will further reshape the competitive landscape.